45 CFR § 180 compliance
B · 85
This hospital published most of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
●Discounted cash price
●Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
3,366
Insurances with rates
19
CPT / HCPCS codes
0
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| 31432_ERX_1 | INJECTION, DIGOXIN IMMUNE FAB (OVINE), PER VIAL | $141,248 | $141,248 | — | — | 30 |
| 135321_ERX_1 | INJECTION, OCRELIZUMAB, 1 MG | $117,244 | $117,244 | — | — | 30 |
| 105472_ERX_1 | LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG | $73,181 | $73,181 | — | — | 30 |
| 122085_ERX_1 | INJECTION, VEDOLIZUMAB, INTRAVENOUS, 1 MG | $53,325 | $53,325 | — | — | 30 |
| 9002_ERX_1 | INJECTION, ALTEPLASE RECOMBINANT, 1 MG | $50,037 | $50,037 | — | — | 30 |
| 40120_ERX_1 | INJECTION, NATALIZUMAB, 1 MG | $48,546 | $48,546 | — | — | 30 |
| 28530_ERX_1 | INJECTION, TENECTEPLASE, 1 MG | $47,181 | $47,181 | — | — | 30 |
| 117719_ERX_1 | INJECTION, IMMUNE GLOBULIN (PRIVIGEN), INTRAVENOUS, NON-LYOPHILIZED (E.G., LIQUID), 500 MG | $42,924 | $42,924 | — | — | 30 |
| 21045_ERX_1 | LEUPROLIDE ACETATE (FOR DEPOT SUSPENSION), 7.5 MG | $36,633 | $36,633 | — | — | 30 |
| 127649_ERX_1 | INJECTION, PEGFILGRASTIM, EXCLUDES BIOSIMILAR, 0.5 MG | $36,514 | $36,514 | — | — | 30 |
| 106463_ERX_1 | INJECTION, IMMUNE GLOBULIN, (GAMMAGARD LIQUID), NON-LYOPHILIZED, (E.G., LIQUID), 500 MG | $29,881 | $29,881 | — | — | 30 |
| 982 | EXTENSIVE O.R. PROCEDURES UNRELATED TO PRINCIPAL DIAGNOSIS WITH CC | $29,802 | $29,802 | — | — | 18 |
| 87691_ERX_1 | FACTOR VIIA (ANTIHEMOPHILIC FACTOR, RECOMBINANT), (NOVOSEVEN RT), 1 MICROGRAM | $28,336 | $28,336 | — | — | 30 |
| 127642_ERX_1 | INJECTION, RITUXIMAB, 10 MG | $26,749 | $26,749 | — | — | 30 |
| 24435_ERX_1 | INJECTION, OCTREOTIDE, DEPOT FORM FOR INTRAMUSCULAR INJECTION, 1 MG | $26,288 | $26,288 | — | — | 30 |
| 744 | D&C, CONIZATION, LAPAROSCOPY AND TUBAL INTERRUPTION WITH CC/MCC | $24,916 | $24,916 | — | — | 18 |
| 3600116_1 | OPERATING ROOM SERVICES - GENERAL CLASSIFICATION | $24,417 | $24,417 | — | — | 26 |
| 10005724_ERX_1 | INJECTION, PEGFILGRASTIM-CBQV (UDENYCA), BIOSIMILAR, 0.5 MG | $23,783 | $23,783 | — | — | 30 |
| 3600115_1 | OPERATING ROOM SERVICES - GENERAL CLASSIFICATION | $19,874 | $19,874 | — | — | 26 |
| 10002388_ERX_1 | Rabies immune globulin for injection beneath the skin and/or into muscle | $19,403 | $19,403 | — | — | 30 |
| 122685_ERX_1 | RYANODEX 250 MG VIAL | $18,898 | $18,898 | — | — | 26 |
| 335 | PERITONEAL ADHESIOLYSIS WITH MCC | $18,153 | $18,153 | — | — | 18 |
| 558 | TENDONITIS, MYOSITIS AND BURSITIS WITHOUT MCC | $18,017 | $18,017 | — | — | 18 |
| 864 | FEVER AND INFLAMMATORY CONDITIONS | $17,497 | $17,497 | — | — | 18 |
| 660 | KIDNEY AND URETER PROCEDURES FOR NON-NEOPLASM WITH CC | $17,250 | $17,250 | — | — | 18 |
| 205 | OTHER RESPIRATORY SYSTEM DIAGNOSES WITH MCC | $17,171 | $17,171 | — | — | 18 |
| 3600114_1 | OPERATING ROOM SERVICES - GENERAL CLASSIFICATION | $17,035 | $17,035 | — | — | 26 |
| 336 | PERITONEAL ADHESIOLYSIS WITH CC | $15,172 | $15,172 | — | — | 18 |
| 128215_ERX_1 | PRAXBIND 5G DOSE(2X 2.5G/50ML) | $14,566 | $14,566 | — | — | 26 |
| 87690_ERX_1 | FACTOR VIIA (ANTIHEMOPHILIC FACTOR, RECOMBINANT), (NOVOSEVEN RT), 1 MICROGRAM | $14,211 | $14,211 | — | — | 30 |
| 176 | PULMONARY EMBOLISM WITHOUT MCC | $12,407 | $12,407 | — | — | 18 |
| 682 | RENAL FAILURE WITH MCC | $12,162 | $12,162 | — | — | 18 |
| 543 | PATHOLOGICAL FRACTURES AND MUSCULOSKELETAL AND CONNECTIVE TISSUE MALIGNANCY WITH CC | $11,973 | $11,973 | — | — | 18 |
| 86442_ERX_1 | INJECTION, FOMEPIZOLE, 15 MG | $11,438 | $11,438 | — | — | 30 |
| 118477_ERX_1 | INJECTION, GOLIMUMAB, 1 MG, FOR INTRAVENOUS USE | $11,433 | $11,433 | — | — | 30 |
| 3611209_1 | Injection of bile duct for X-ray through new skin access using imaging guidance with review by radio | $11,281 | $11,281 | — | — | 30 |
| 091 | OTHER DISORDERS OF NERVOUS SYSTEM WITH MCC | $11,263 | $11,263 | — | — | 18 |
| 561 | AFTERCARE, MUSCULOSKELETAL SYSTEM AND CONNECTIVE TISSUE WITHOUT CC/MCC | $10,676 | $10,676 | — | — | 18 |
| 571 | SKIN DEBRIDEMENT WITH CC | $10,301 | $10,301 | — | — | 18 |
| 330 | MAJOR SMALL AND LARGE BOWEL PROCEDURES WITH CC | $10,271 | $10,271 | — | — | 18 |
| 76527_ERX_1 | INJECTION, NALTREXONE, DEPOT FORM, 1 MG | $9,680 | $9,680 | — | — | 30 |
| 3001460_1 | Molecular pathology procedure level 9 genetic analysis | $9,475 | $9,475 | — | — | 30 |
| 3002264_1 | Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion vari | $9,449 | $9,449 | — | — | 30 |
| 3100535_1 | Gene analysis (breast cancer 1 and 2) of full sequence and analysis for duplication or deletion vari | $9,448 | $9,448 | — | — | 30 |
| 175 | PULMONARY EMBOLISM WITH MCC OR ACUTE COR PULMONALE | $9,158 | $9,158 | — | — | 18 |
| 3600113_1 | OPERATING ROOM SERVICES - GENERAL CLASSIFICATION | $9,085 | $9,085 | — | — | 26 |
| 6100155_1 | MRI scan of both breasts | $8,995 | $8,995 | — | — | 30 |
| 118499_ERX_1 | INJECTION, FERRIC CARBOXYMALTOSE, 1 MG | $8,811 | $8,811 | — | — | 30 |
| 3100249_1 | Test for detecting genes associated with heart disease, genomic sequence analysis panel, at least 9 | $8,800 | $8,800 | — | — | 30 |
| 70287_ERX_1 | INJECTION, ABATACEPT, 10 MG (CODE MAY BE USED FOR MEDICARE WHEN DRUG ADMINISTERED UNDER THE DIRECT S | $8,677 | $8,677 | — | — | 30 |
Showing top 50 of 3,366 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.